You are here: Industry Insights > Kymriah

News List

Novartis’ CAR T therapy Kymriah shows promise in follicular lymphoma pharmatimes
June 04, 2021
Novartis’ CAR T therapy Kymriah has shown promise for the treatment of relapsed or refractory follicular lymphoma – the second most common form of non-Hodgkin lymphoma (NHL).
Novartis receives approval for Kymriah (tisagenlecleucel) by Health Sciences Authority as Singapore's first commercially approved CAR-T therapy prnasia
March 11, 2021
Novartis announced that the Health Sciences Authority (HSA) has approved Kymriah (tisagenlecleucel) as the first commercial chimeric antigen receptor T-cell (CAR-T) therapy in Singapore under the new cell, tissue and gene therapy products (CTGTP) ...
CAR T therapy provides long-lasting remissions in non-hodgkin lymphoma europeanpharmaceuticalreview
February 20, 2021
Study shows most non-Hodgkin’s lymphoma patients who achieve a remission lasting one year remain in remission for five years after receiving Novartis’ Kymriah™.
Novartis Expands with Kymriah Manufacturing Site in Asia americanpharmaceuticalreview
November 11, 2020
Novartis announced the receipt of marketing authorization from Japan’s Ministry of Health, Labor and Welfare (MHLW) for Foundation for Biomedical Research and Innovation at Kobe (FBRI) to manufacture and supply commercial Kymriah® (tisagenlecleucel) for..
Novartis Expands Kymriah Manufacturing Footprint contractpharma
November 05, 2020
Novartis has received marketing authorization from Japan’s Ministry of Health, Labor and Welfare (MHLW) for Foundation for Biomedical Research and Innovation at Kobe (FBRI) to manufacture and supply commercial Kymriah (tisagenlecleucel) for patients ...
Novartis’ CAR-T therapy Kymriah hits endpoint in follicular lymphoma trial pharmatimes
August 05, 2020
Novartis has revealed positive results from a phase 2 study of its CAR-T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory follicular lymphoma.
Kymriah Receives FDA Regenerative Medicine Advanced Therapy Designation americanpharmaceuticalreview
April 26, 2020
Novartis announced the US Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kymriah® (tisagenlecleucel).
FDA grants RMAT designation to Novartis’ Kymriah in follicular cancer pharmaceutical-technology
April 23, 2020
The US Food and Drug Administration (FDA) has awarded regenerative medicine advanced therapy (RMAT) designation to Novartis’ Kymriah (tisagenlecleucel) to treat relapsed or refractory (r/r) follicular lymphoma (FL).
Novartis’ Kymriah Gets RMAT Designation contractpharma
April 23, 2020
Investigational new indication to treat patients with relapsed or refractory follicular lymphoma.
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting pharmaceutical-business-review
December 12, 2019
Novartis announced results from two analyses of real-world experience with Kymriah (tisagenlecleucel), the only CAR-T cell therapy approved in two distinct indications.

Previous page 1 2 3 4 Next page